Celestial Therapeutics is at the forefront of developing innovative therapies aimed at treating, preventing, and curing infectious diseases, rare diseases, and cancers. The company leverages its proprietary lipid and Stellar mRNA technology platforms to create next-generation antivirals, anti-inflammatories, and mRNA vaccines. These technologies are rooted in extensive research conducted by leading scientists, including Dr. George Church from Harvard Medical School, and focus on enhancing innate immune responses. The Stellar mRNA platform, in particular, utilizes short noncoding immunostimulatory RNA sequences to boost immune responses, leading to increased expression of interferons and cytokines, which are crucial for fighting infections and cancer.

Celestial's lipid platform is based on naturally occurring pulmonary surfactant lipids, which are essential for maintaining lung function and immune regulation. The lead molecule, CT-02, is an endogenous phospholipid that has shown promise as a dual modal antiviral and anti-inflammatory agent, particularly against respiratory viruses such as Respiratory Syncytial Virus (RSV) and H1N1. The company is currently prioritizing the development of CT-02 for RSV treatment, aiming to address significant unmet medical needs in respiratory infections. Through these advanced technologies, Celestial Therapeutics is committed to delivering safer and more effective therapeutic options for a variety of health challenges.

United States

Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious diseases, rare diseases and cancers.

Celestial Therapeutics

Company Details